Abstract
Advanced age is a main risk factor for severe COVID-19. However, low vaccination efficacy and accelerated waning immunity have been reported in this age group. To elucidate age-related differences in immunogenicity, we analysed human cellular, serological and salivary SARS-CoV-2 spike glycoprotein-specific immune responses to BNT162b2 COVID-19 vaccine in old (69-92 years) and middle-aged (24-57 years) vaccinees compared to natural infection (COVID-19 convalescents, 21-55 years). Serological humoral responses to vaccination exceeded those of convalescents but salivary anti-spike subunit 1 (S1) IgA and neutralizing capacity were less durable in vaccinees. In old vaccinees, we observed that pre-existing spike-specific CD4+ T cells are associated with efficient induction of anti-S1 IgG and neutralizing capacity in serum but not saliva. Our results suggest pre-existing SARS-CoV-2 cross-reactive CD4+ T cells as predictor of an efficient COVID-19 vaccine-induced humoral immune response in old individuals.
Competing Interest Statement
VMC and MAM are named together with Euroimmun on a patent application filed recently regarding detection of antibodies against SARS-CoV-2.
Funding Statement
German Federal Ministery of Health to AT (Charite Corona Cross (CCC)) and to CD and VMC (Konsiliarlabor fuer Coronaviren). German Ministry of Research through VARIPath (01KI2021) to VMC. German Research Foundation through KFO339 to JB. In part by the German Federal Ministry of Education and Research (Bundesministerium fuer Bildung und Forschung, BMBF) to NaFoUniMedCovid19, COVIM, FKZ 01KX2021.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics Committee Charite - Universitaetsmedizin Berlin
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Missing Figure data added.
Data Availability
The datasets generated during the current study are available from the corresponding author on reasonable request.
Abbreviations
- COVID-19
- coronavirus disease 2019
- d28
- day 28 after first vaccination
- d49
- day 49 after first vaccination
- ∼d28
- around day 28 after COVID-19 symptom onset
- ∼d49
- around day 49 after COVID-19 symptom onset
- ∼d94
- around day 94 after COVID-19 symptom onset
- SARS-CoV-2
- severe acute respiratory syndrome coronavirus 2
- sIgA
- secretory IgA
- sVNT
- surrogate virus neutralization assay
- S1
- SARS-CoV-2 spike glycoprotein subunit 1
- S-I
- peptide mix representing the SARS-CoV-2 spike glycoprotein N-terminal part
- S-II
- peptide mix representing the SARS-CoV-2 spike glycoprotein C-terminal part mix
